| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
CS-2100 targets the S1P1 receptor, a G protein-coupled receptor involved in immune cell trafficking and lymphocyte egress. It acts as a potent and selective agonist with an EC50 of 4.0 nM for human S1P1. It is S1P3-sparing, meaning it does not activate S1P3 receptors.
|
|---|---|
| ln Vitro |
CS-2100 is a potent S1P1 agonist with an EC50 of 4.0 nM for human S1P1. It is selective for S1P1 over S1P3. By activating S1P1, it modulates immune cell trafficking.
|
| ln Vivo |
CS-2100 has been found to exhibit activities in animal's adjuvant-induced arthritis model. It is an orally active compound. It modulates immune cell trafficking through S1P1 activation.
|
| Enzyme Assay |
CS-2100 is evaluated in cell-free receptor binding assays to determine its affinity for S1P1 and other S1P receptors. Radioligand binding displacement assays are performed using membrane preparations expressing S1P receptor subtypes. Competition binding experiments are conducted with increasing concentrations of CS-2100 and a fixed concentration of a labeled reference ligand.
|
| Cell Assay |
CS-2100 is assessed in cell-based functional assays to measure its agonist activity at S1P1. Cells expressing S1P1 are treated with CS-2100, and receptor activation is measured by assessing downstream signaling pathways, such as GTPγS binding or cAMP inhibition. EC50 values are determined.
|
| Animal Protocol |
CS-2100 is administered orally in animal models to evaluate its effects on immune cell trafficking and inflammation. It has been studied in models of arthritis. Efficacy is assessed by measuring inflammatory markers and disease severity.
|
| ADME/Pharmacokinetics |
CS-2100 has a molecular weight of 461.53 and a molecular formula of C25H23N3O4S. It has a CAS number of 913827-99-3. The compound is soluble in DMSO. It should be stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CS-2100. The compound is for research use only and is not intended for human therapeutic use. It is a potent S1P1 agonist used in research on immune-mediated diseases.
|
| References | |
| Additional Infomation |
CS-2100 is a potent, selective, orally active S1P1 agonist. It is also known as CS 2100. It is S1P3-sparing. It is not approved for clinical use.
|
| Molecular Formula |
C25H23N3O4S
|
|---|---|
| Molecular Weight |
461.532824754715
|
| Exact Mass |
461.14
|
| CAS # |
913827-99-3
|
| PubChem CID |
11977938
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
33
|
| Complexity |
650
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1CN(CC2=CC(CC)=C(C3N=C(C4C=CC(OC5C=CC=CC=5)=CC=4)ON=3)S2)C1)O
|
| InChi Key |
DWVJASHDNJMDNH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H23N3O4S/c1-2-16-12-21(15-28-13-18(14-28)25(29)30)33-22(16)23-26-24(32-27-23)17-8-10-20(11-9-17)31-19-6-4-3-5-7-19/h3-12,18H,2,13-15H2,1H3,(H,29,30)
|
| Chemical Name |
1-[[4-ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]thiophen-2-yl]methyl]azetidine-3-carboxylic acid
|
| Synonyms |
CS2100; CS 2100; CS-2100
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~27.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1667 mL | 10.8335 mL | 21.6671 mL | |
| 5 mM | 0.4333 mL | 2.1667 mL | 4.3334 mL | |
| 10 mM | 0.2167 mL | 1.0834 mL | 2.1667 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
